Cómo se integra el ADN proviral en el ADN de la célula del huésped y cómo se puede inhibir el proceso

Mirambeau, Gilles.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 26(supl.12): 11-16, nov. 2008.
Artículo en Es | IBECS (España) | ID: ibc-71186

Documentos relacionados

  1. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
  2. Human pharmacokinetics prediction with an <i>in vitro</i>-<i>in vivo</i> correction factor approach and <i>in vitro</i> drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy<sup>®</sup> for the treatment of HIV-1 infection.
  3. Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review.
  4. Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
  5. The FACT Complex Promotes Avian Leukosis Virus DNA Integration.
  6. Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial.
  7. DNA arms do the legwork to ensure the directionality of lambda site-specific recombination.
  8. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.
  9. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
  10. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.